Similarly, we found an increase in CSF GFAP in patients with early-onset AD compared to younger controls, but again perhaps due to the increase in CSF levels of GFAP with age (Vagberg et al., 2015), this difference was lost between late-onset AD and older controls. This evidence concerns the gene GFAP and Alzheimer disease.